Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies David Bredt files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Third Rock Ventures V, L.P. - $34.39M of RAPP open-market activity in the last 12 months
- Abraham Ceesay - $7.62M of RAPP open-market activity in the last 12 months
- Krishnaswamy Yeleswaram - $4.46M of RAPP open-market activity in the last 12 months
- Cheryl Gault - $1.10M of RAPP open-market activity in the last 12 months
- Steven M. Paul - $1.03M of RAPP open-market activity in the last 12 months
- Reid M. Huber - $499K of RAPP open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is David Bredt?
David Bredt is a corporate insider, tracked as Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did David Bredt last file a Form 4?
The most recent primary Form 4 on record is dated 20 February 2026, one of 10 filings going back to 2025.
Has David Bredt been buying or selling stock?
Recorded transactions: 0 open-market purchases and 17 open-market sales ($1.81M) across all tracked filings.
Where can I see all of David Bredt's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow David Bredt and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
